JOURNAL ARTICLES
Access peer-reviewed journal articles sponsored by Dyne Therapeutics offering insights into the FORCE™ platform.
The FORCE™ platform, zeleciment-basivarsen (z-basivarsen, formerly known as DYNE-101), zeleciment-rostudirsen (z-rostudirsen, formerly known as DYNE-251), DYNE-302, and DYNE-401 are investigational or otherwise in development and have not been approved as safe or effective by the US FDA, EMA or any other regulatory authority.
FORCE platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy features in preclinical models
Patient engagement in clinical trial design for rare neuromuscular disorders: impact on the DELIVER and ACHIEVE clinical trials
Enhanced exon skipping and prolonged dystrophin restoration achieved by TfR1-targeted delivery of antisense oligonucleotide using FORCE conjugation in mdx mice
Changes in RNA splicing as a surrogate endpoint for Myotonic Dystrophy Type 1 (DM1) clinical trials